Tryp Therapeutics: Unlocking the potential of psychedelic medicine

CSE: TRYP | OTCQB: TRYPF

The New Era of Psychedelic Medicine

September 22, 2021

Tryp Therapeutics submits IND Application for Phase 2A Clinical Trail in eating disorders

September 1, 2021

Tryp Therapeutics to present at H.C. Wainwright Global Investment Conference

August 24, 2021

Tryp Therapeutics completes Psychotherapy Training for Phase 2A study University of Florida

By clicking “submit”, I agree to be contacted by Tryp Therapeutics and understand that I may opt-out at any time.

View Privacy Policy